



# Effects of Dairy Matrix on Musculoskeletal Health


René Rizzoli Service of Bone Diseases Geneva University Hospitals and Faculty of Medicine Geneva, Switzerland

Dublin, October 16 2019



# Disclosure

Speaker Bureau or Member of Scientific Advisory Boards for Abiogen, Danone, Echolight, Effryx, Mylan, Nestlé, ObsEva, Pfizer, Radius Health, Sandoz, TEVA/Theramex





Can Bone Mineral Mass Trajectory be Changed ? Nutritional Factors: Calcium, Protein (Dairy)







Children Bone Mass in Relation to Mother Nutritional Status during Pregnancy


- WB BMD at Age of 6 Yrs was Positively Correlated to Milk Products and Calcium-rich Foods Consumption During Pregnancy (Ganpule et al 2006)

- At the Age of 8-9 Years, aBMD (WB-BMC) was Higher if Born from a Mother with a Prudent Diet (Fruits, Vegetables, Pasta, yoghourt, Cheese) (Cole et al 2009)

> Cross-sectional Case Control Studies



# 6 year milk intake and offspring (at 6 years) associated bone mass



Kindly provided by Cole et al 2013



## **Randomized Controlled Trials**

Milk consumption and the growth of school children


Orr BMJ 1928 Leighton & Clark BMJ 1929

400-600 ml Milk -> Greater Height Gain



## Milk Intake and BMC Acquisition in Adolescent Girls

Cadogan et al, BMJ 1997






# Effect of Dairy on Bone Mass Accrual in Children and Adolescents (RCT)

Billion Study	n	Age(yr)	Duration	Intervention	Main Results		
Matkovic 1990	28	14	2 yr	Milk 900 ml	NS		
Chan 1995	46	11	1 yr	Dairy (1437 mg/d calcium	Increased LS BMD & WB BMC		
Cadogan 1997	80	12.2	18 mo	Milk (486 ml/d)	Increased WB BMC & BMD		
Renner 1998	129	15.5	1 yr	Dairy (1150 mg/d calcium)	Increased Forearm BMD		
Merrilees 2000	73	15.5	1 yr	Dairy (1160 mg/d calcium)	Increased LS, FN & Troch BMD		
Volek 2003	28	14.3	12 wks	Dairy (3 servings)	Increased WB BMD		
Gibbons 2004	123	9.4	18 mo	Dairy	NS (LS, Hip & WB BMD)		
Lau 2004	324	10	18 mo	Dairy (fortified milk)	Increased LS & Hip BMD		
Du 2004	698	10	2 yr	Dairy	Increased WB BMC & BMD		
Cheng 2005	173	11	2 yr	Dairy (Cheese)	Increased WB BMD & Tibia Cortical Thickness		
Albala 2008	93	9 yr	16 wks	Dairy (3 Servings)	NS (WB BMC)		



## Nutritional Influences on Bone Growth in Children

Cortical Area Proximal Radius (mm<sup>2</sup>)




Dairy versus high or low calcium, P=0.0003 by ANOVA

Matkovic et al J Nutr 2004



### Effects of Calcium, Dairy Products or Vitamin D on Bone Mass Accrual in 10-12 Years Old Girls: a 2-Year RCT Cheng et al, AJCN 2005



ITT and Per Protocol



### Effects of Milk and Milk-Product Consumption on Growth among Children and Adolescents Aged 6-18 Years: A Meta-Analysis of Randomized **Controlled Trials**

Mean Difference

Mean Difference

-0.05 [-0.11, 0.01]

0.10 [-0.25, 0.45]

0.37 [-0.67, 1.41]

4.4% -3.33 [-4.60, -2.06]

5.0% -1.67 [-2.78, -0.56]

Mean Difference

Mean Difference

IV. Random, 95% CI

-1

Favors [intervention]] Favors [contro]

					Control		mean princience	THE BELLE PROPERTY OF THE PROP			
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random,	95% CI
	Albala et al. (22)	0.92	0.1	47	0.62	0.11	46	15.0%	0.30 [0.26, 0.34]		
	Cadogan et al. (25)	5.5	0.99	44	5.05	0.81	38	9.5%	0.45 [0.06, 0.84]		-
	Chan et al. (26)	4.3	0.6	22	3.8	1	26	8.3%	0.50 [0.04, 0.96]		-
	Cheng et al. (27)	7.64	1.41	39	8.37	1.46	38	5.8%	-0.73 [-1.37, -0.09]		
I R <i>A</i>	Cohen et al. 1 (28)	0.1	6.69	24	1.33	6.32	26	0.3%	-1.23 [-4.84, 2.38]		
Lean Mass	Cohen et al. 2 (28)	0.41	6.19	23	1.33	6.32	26	0.3%	-0.92 [-4.43, 2.59]		
	Gibbons et al. (30)	3.98	0.19	74	3.81	0.18	80	14.9%	0.17 [0.11, 0.23]	-	
	Lambourne et al. (31)	2.2	1.9	36	1.7	2.9	38	2.6%	0.50 [-0.61, 1.61]	-	
	Lappe et al. (32)	0.05	0.35	136	0.03	0.26	138	14.8%	0.02 [-0.05, 0.09]	-	
	Merrilees et al. (33)	0.72	0.09	45	0.12	0.06	46	15.0%	0.60 [0.57, 0.63]		
	Volek et al. (38)	2.4	0.3	14	2.4	0.2	14	13.3%	0.00 [-0.19, 0.19]	+	
	Total (95% CI)			504			516	100.0%	0.21 [0.01, 0.41]	•	
	Heterogeneity: Tau2 =	0.07; Cł	1i <sup>2</sup> = 3	69.71,	df = 10	0 (P < )	0.0000	1); I <sup>2</sup> = 97	7%		
	Test for overall effect:	Z = 2.10	) (P =	0.04)						Favors (control) Fa	vors [intervention]

Control

Control

23 3.27 1.96 26

Mobarhan et al. 1 (34) -1.78 0.18 33 -1.5 0.29 35 12.0% -0.28 [-0.39, -0.17] Mobarhan et al. 2 (34) -1.51 0.3 28 -1.5 0.29 35 11.6% -0.01 [-0.16, 0.14]

407

Heterogeneity: Tau<sup>2</sup> = 0.07; Chi<sup>2</sup> = 90.15, df = 9 (P < 0.00001); l<sup>2</sup> = 90%

Test for overall effect: Z = 3.00 (P = 0.003)

-2.2 0.3 14 -1.4 0.4 14 9.9% -0.80 [-1.06, -0.54]

Mean SD Total Mean SD Total Weight IV, Random, 95% CI

46

38

9.3%

8.6%

5.3%

+ 21%

А

B

Study or Subgroup

Cadogan et al. (25)

Cheng et al. (27)

Cohen et al. 1 (28)

Cohen et al. 2 (28)

Volek et al. (38) Total (95% CI)

Albala et al. (22)

Intervention

Intervention

1.6 1.98

0.84 0.15 47 0.89 0.15

1.84 0.75 44 1.74 0.86

3.42 2.31 39 3.05 2.33 38

-0.06 2.55 24 3.27 1.96 26

CONCILCT OF ALL & LEOT	4.00	1.20	6.3	3.6.1	1.20	2.0		-1.01 [-1.10, -0.30]	
Gibbons et al. (30)	2.59	0.25	74	2.33	0.29	80	9.2%	0.26 [0.17, 0.35]	*
Lambourne et al. (31)	1.1	2.8	36	0.4	3.6	38	3.7%	0.70 [-0.77, 2.17]	
Merrilees et al. (33)	2.62	0.05	45	2.56	0.09	46	9.3%	0.06 [0.03, 0.09]	•
Mobarhan et al. 1 (34)	-2.26	0.1	33	-3.4	0.02	35	9.3%	1.14 [1.11, 1.17]	
Mobarhan et al. 2 (34)	-4.32	0.94	28	-3.4	0.02	35	8.6%	-0.92 [-1.27, -0.57]	~
Vogel et al. 2 (37)	1.68	0.2	47	1.51	0.17	32	9.2%	0.17 [0.09, 0.25]	*
Vogel et al. 3 (37)	1.35	0.15	55	1.51	0.21	47	9.3%	-0.16 [-0.23, -0.09]	-
Volek et al. (38)	-1.1	0.4	14	-0.8	0.3	14	8.9%	-0.30 [-0.56, -0.04]	
Total (95% CI)			509			501	100.0%	-0.15 [-0.52, 0.22]	•
Heterogeneity: $Tau^2 = 0$ Test for overall effect: Z				df = 1	2 (P < 1	0.0000	(1); $\Gamma = 10$	00%	-4 -2 0 2
Test for overall effect: 2	2 = 0.80		.42)		ontrol		(1); 1" = 10	Mean Difference	-4 -2 Ó 2 Favors [intervention] Favors [control] Mean Difference
Test for overall effect: 2	2 = 0.80	(P = 0	.42)				Weight		
Test for overall effect: 2 C Study or Subgroup	: = 0.80	(P = 0 rventi SD	.42) on	c	ontrol SD			Mean Difference	Mean Difference
Test for overall effect: 2 C Study or Subgroup	Inte Mean	(P = 0 rventi SD 0.24	on Total	C Mean	ontrol SD 0.25	Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Test for overall effect: 2 C Study or Subgroup Albala et al. (22) Cadogan et al. (25)	Inte Mean 0.36	(P = 0 rventi SD 0.24	0n Total 47	C Mean 0.78	ontrol SD 0.25	Total 46	Weight 12.1%	Mean Difference IV, Random, 95% CI -0.42 [-0.52, -0.32]	Mean Difference IV, Random, 95% Cl
Test for overall effect: 2 Study or Subgroup Albala et al. (22) Cadogan et al. (25) Chan et al. (26)	Inte Mean 0.36 -0.42	(P = 0 rventi SD 0.24 0.29	on Total 47 44	0.78 0.12	ontrol SD 0.25 0.31 0.4	Total 46 38	Weight 12.1% 11.8%	Mean Difference IV, Random, 95% CI -0.42 [-0.52, -0.32] -0.54 [-0.67, -0.41]	Mean Difference IV, Random, 95% Cl
Test for overall effect: 2 C Study or Subgroup Albala et al. (22) Cadogan et al. (25) Chan et al. (26) Cohen et al. 1 (28)	Inte Mean 0.36 -0.42 1.6	(P = 0 rventi 5D 0.24 0.29 0.6 0.59	on <u>Total</u> 47 44 22	0.78 0.12 1.2	0.25 0.31 0.4 0.35	Total 46 38 26	Weight 12.1% 11.8% 9.4%	Mean Difference IV, Random, 95% CI -0.42 [-0.52, -0.32] -0.54 [-0.67, -0.41] 0.40 [0.11, 0.69]	Mean Difference IV, Random, 95% Cl
Test for overall effect: 2 C Study or Subgroup Albala et al. (22) Cadogan et al. (25) Chan et al. (26)	Inte Mean 0.36 -0.42 1.6 -0.67	(P = 0 rventi 5D 0.24 0.29 0.6 0.59	on Total 47 44 22 24	C Mean 0.78 0.12 1.2 -0.1	0.25 0.31 0.4 0.35	Total 46 38 26 26	Weight 12.1% 11.8% 9.4% 9.7%	Mean Difference IV, Random, 95% CI -0.42 [-0.52, -0.32] -0.54 [-0.67, -0.41] 0.40 [0.11, 0.69] -0.57 [-0.84, -0.30]	Mean Difference IV, Random, 95% Cl
Test for overall effect: 2 C Study or Subgroup Albala et al. (22) Chan et al. (25) Chan et al. (26) Cohen et al. 1 (28) Cohen et al. 2 (28)	Inte Mean 0.36 -0.42 1.6 -0.67 -0.33	(P = 0 rventi <u>SD</u> 0.24 0.29 0.6 0.59 0.39	on Total 47 44 22 24 23	C Mean 0.78 0.12 1.2 -0.1 -0.1	0.25 0.31 0.4 0.35 0.35	Total 46 38 26 26 26 26	Weight 12.1% 11.8% 9.4% 9.7% 10.7%	Mean Difference IV. Random. 95% CI -0.42 [-0.52, -0.32] -0.54 [-0.67, -0.41] 0.40 [0.11, 0.69] -0.57 [-0.84, -0.30] -0.23 [-0.44, -0.02]	Mean Difference IV, Random, 95% Cl

422 100.0% -0.27 [-0.45, -0.09]

- 27%

% Fat





## Dairy Products and Fracture Risk In Childhood and Adolescence

1.Children who avoid drinking cow's milk are at increased risk for prepubertal bone fractures *Goulding et al, JADA 2004* 

-> 0 - 13 yrs: 22 observed fractures vs 8.4 expected

2. Fractures during growth: potential role of a milk-free diet *Konstantynowicz et al, Osteoporos Int 2007* 

-> 2 - 20 yrs: OR 4.6 in girls and 1.3 (NS) in boys




## **Recommended Milk Intakes**

US Department of Agriculture Food Pyramid US Department of Health & Human Services Dietary Guidelines for American

Children 2 - 8 Yrs 480 ml or Equivalent

> 9 Yrs 730 ml or Equivalent








The Impact of Dairy Protein Intake on Muscle Mass, Muscle Strength, and Physical Performance in Middle-Aged to Older Adults with or without Existing Sarcopenia: A Systematic Review and Meta-Analysis

	Dairy protein Control							Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Alemán-Mateo et al. (20)	0.3	1.9	20	0.2	1.77	20	1.2%	0.10 [-1.04, 1.24]	· · · · · · · · · · · · · · · · · · ·
Alemán-Mateo et al. (26)	0	2.62	49	-0.2	2.59	49	1.4%	0.20 [-0.83, 1.23]	
Arnarson et al. (27)	0.6	1.2	66	0.5	0.8	75	11.5%	0.10 [-0.24, 0.44]	
Bauer et al. (21)	0.25	0.68	124	0.08	0.68	135	34.2%	0.17 [0.00, 0.34]	
Norton et al. (33)	0.27	0.59	31	-0.01	0.36	29	19.8%	0.28 [0.03, 0.53]	
Tieland et al. (24)	0.1	1.13	31	0.1	1.13	31	4.6%	0.00 [-0.56, 0.56]	
Verreijen et al. (28)	0.4	1.2	30	-0.5	2.1	30	2.0%	0.90 [0.03, 1.77]	
Zhu et al. (30)	-0.03	0.67	93	0.03	0.75	88	25.4%	-0.06 [-0.27, 0.15]	-
Total (95% CI)			444			457	100.0%	0.13 [0.01, 0.26]	<ul> <li>+ 13%</li> </ul>
Heterogeneity: Tau <sup>2</sup> = 0.0	0; Chi <sup>2</sup> =	8.17.	df = 7	(P = 0.	32); I <sup>2</sup>	= 14%			
Test for overall effect: Z =									-2 -1 0 1 2 Control Dairy protein



#### A DAIRY-BASED PROTEIN, CALCIUM AND VITAMIN D SUPPLEMENT REDUCES FALLS AND FEMORAL NECK BONE LOSS IN AGED CARE RESIDENTS: A CLUSTER RANDOMISED TRIAL


813 Age Care Residents, 86.1 $\pm$ 5.9 Yrs, 76% Women,  $\pm$  Dairy-based protein (9 g/d), calcium (600 mg/d) and vitamin D (960 IU/d), for 8 Months after a 12-Month observation Period **OR for Risk of Falls** 



Iuliano-Burns et al J Aging Res Clin Pract 2012



Change in BMD by tertile of protein intake (% energy) in 342 men and women (aged  $\geq$  65 yr) treated with calcium (500 mg/d) and vitamin D (700 IU/d) ( $\blacksquare$ ) or placebo ( $\Box$ ) for 3 years




Dawson-Hughes et al AJCN 2002



## Effects of Fortified Dairy Products

Whole Body BMD

Lumbar Spine BMD



Moschonis et al Br J Nutr 2010

Ting et al JNHA 2007




## Effect of Dairy on Bone Mineral Density in Adults (RCT)

Study	n	Age(yr)	Duration	Intervention	Main Results
Lau 2001	185	PM Women	2 yr	Milk Powder	Lower BMD Decrease
Chee 2003	173	55-65	2 yr	Milk Powder	Lower BMD Decrease
Manios 2007	101	PM Women	5 mo	Milk & Yogurt	Higher LS and WB BMD
Daly 2006	111	50-87	2 yr	Fortified Milk	Lower Hip & Radius BMD Decrease
Thorpe 2008	130	30-65	1 yr	Dairy	Lower BMD Decrease
Moschonis 2010	66	55-65	30 mo	Fortified Milk & Yogurt	Increased WB BMD
Moschonis 2011	115	PM Women	12 mo	Fortified Milk & Yogurt	Increased WB BMD
Gui 2012	141	45-65	18 mo	Milk	Lower Hip BMD Decrease

Adapted from Rizzoli et al Osteoporos Int 2018



## Dairy product intake and bone properties in 70-year-old men and women



Hallkvist et al Arch Osteoporos 2018




Peripheral skeleton bone strength is positively correlated with total and dairy protein intakes in healthy postmenopausal women<sup>1,2</sup>

> 6300 6200


6100

6000


<13.8 g/d






















13.8 - 23.2 g/d

**Dairy proteins** 

>23.2 g/d







Durosier-Izart et al AJCN 2017



High dairy protein intake is associated with greater bone strength parameters at the distal radius and tibia in older men: a cross-sectional study

L. Langsetmo<sup>1</sup> · J. M. Shikany<sup>2</sup> · A. J. Burghardt<sup>3</sup> · P. M. Cawthon<sup>4,5</sup> · E. S. Orwoll<sup>6</sup> ·

J. A. Cauley<sup>7</sup> · B. C. Taylor<sup>1,8,9</sup> · J. T. Schousboe<sup>10,11</sup> · D. C. Bauer<sup>12</sup> · T. N. Vo<sup>1</sup> ·

K. E. Ensrud<sup>1,8,9</sup> · for the Osteoporotic Fractures in Men (MrOS) Study Research Group

Osteoporosis International 29:69-77,2018

1016 Men, Mean Age 84.3 Yrs (MrOs), FFQ, Protein Intakes in Percent of Energy Intakes HR-pQCT

- Dairy Protein
  - -> Higher Calculated Bone Strength (Effect Size: 0.17 at radius et 0.13 at tibia)
- Non Dairy Animal Protein
  - -> Higher Calculated Bone Strength (radius)
- Vegetable Protein: No Effect



## Milk and other dairy foods and risk of hip fracture in men and women

D. Feskanich<sup>1</sup> · H. E. Meyer<sup>2,3</sup> · T. T. Fung<sup>4</sup> · H. A. Bischoff-Ferrari<sup>5</sup> · W. C. Willett<sup>1,6</sup>

Osteoporosis International 29:385-396, 2018

Nurses' Health Study & Health Professionals Follow-up Study:

80'600 Postmenopausal Women 43'306 Men -> 32 Yrs Follow-Up (Survey every 4 Yrs) 2138 & 694 Hip Fractures

Hip Fracture Risk :

- - 8 % per Milk Serving (240 ml)
- - 9 % per Cheese Serving (28 g) (NS)
- 6 % per Dairy Products Serving



HR

1

## Fermented Dairy Products and Hip Fracture Risk

Swedish Mammographic Cohort 61'433 Women 39-74 ans; Follow-up: 20.1 aYrs 4'259 Hip Fractures

0.88

(0.67-0.78) (0.80-0.97) (0.55-0.74)

• Yogurt and Fermented Milk

	<1g/d	1-199g/d	200-399g/d	>=400g/d
HR	1	0.73 (0.68-0.79)	0.84 (0.70-0.93)	0.70 (0.57-0.86)
	• (	Cheese		
	<20g/d	20-39g/d	40-59g/d	>=60g/d

0.72

For each Serving (200 g Yogurt Or 20g Cheese): Minus 10 -15% Hip Fracture Risk

Michaëlsson K et al. BMJ 2014

0.64



### Effects of Milk and Dairy Products on the Prevention of Osteoporosis and Osteoporotic Fractures in <u>Europeans</u> and <u>Non-Hispanic Whites</u> from North America: A Systematic Review and Updated Meta-Analysis

HR for
Incident
Fracture at
any Site
(n=109'134)

Reference		Hazard	%
ID	Gender	ratio (95% CI)	Weight
Milk			
Michaëlsson (2014)[33]	Men	1.03 (0.94, 1.11)	13.52
Michaëlsson (2014) <sup>[33]</sup>	Women	1.16 (1.08, 1.25)	13.92
Kalkwarf (2003)[30]	Men + Women	0.84 (0.59, 1.20)	4.27
Feart (2013) [34]	Men + Women	0.91 (0.65, 1.27)	4.64
Subtotal (I-squared = 61.3% P= 0.051)	$\Diamond$	1.05 (0.94, 1.18)	36.35
Cheese	i i		
Michaëlsson (2014) <sup>[33]</sup>	Men	0.95 (0.88, 1.04)	13.51
Michaëlsson (2014)[33]	Women	0.85 (0.81, 0.90)	14.62
Feart (2013)[34]	Men + Women	0.88 (0.62, 1.23)	4.49
Subtotal (I-squared = 59.0%, P = 0.087)		0.89 (0.81, 0.98)	32.62
Yogurt			
Michaëlsson (2014) <sup>[33]</sup>	Men Men	0.95 (0.87, 1.03)	13.47
Michaëlsson (2014)[33]	Women	0.90 (0.82, 0.99)	13.06
Feart (2013)[34]	Men + Women	0.78 (0.55, 1.09)	4.50
Subtotal (I-squared = 0.0%, <i>P</i> = 0.437)	0	0.92 (0.87, 0.98)	31.03
Overall (I-squared = 82.9%, P < 0.001)	$\diamond$	0.95 (0.87, 1.03)	100.00
NOTE: Weights are from random effects analysis			
0.2	1.0 1.5 2.0 3	3.5	

Matia-Martin et al Adv Nutr 2019



Cohort


# Dairy product consumption and risk of hip fracture: a systematic review and metaanalysis

Type = Milk Sahni 2014 Owusu 1997 Meyer(Female) 1997 Fujiwara 1997 Cumming 1997 Michaelsson (Female) 2014 Michaelsson (Male) 2014 Feskanich (NHS) 2014 Feskanich (HPFS ) 2014 Feat 2013 Kanis(Female) 2004 Kanis(Male) 2004 Random effects model Heterogeneity: J <sup>2</sup> = 75%, p < 0.01		0.58 [0.31; 1.07] 0.97 [0.39; 2.42] 0.83 [0.44; 1.56] 0.46 [0.22; 0.97] 0.54 [0.26; 1.12] 0.90 [0.49; 1.66] 1.60 [1.39; 1.84] 1.01 [0.78; 1.31] 1.21 [0.86; 1.70] 0.86 [0.50; 1.48] 0.92 [0.69; 1.22] 0.66 [0.39; 1.12] 0.91 <b>[0.74; 1.12]</b>	2.9% 1.7% 2.2% 2.3% 6.3% 6.1% 4.8% 5.4% 5.4% 5.2% 3.4% 4.8% 5.2% 4.9%	
Type = Yogurt Sahni 2014 Michaelsson (Female) 2014 Michaelsson (Male) 2014 Feart 2013 Random effects model Heterogeneity: J <sup>2</sup> = 0%, p = 0.42		1.09 [0.65; 1.82] 0.70 [0.57; 0.86] 0.75 [0.63; 0.90] 0.90 [0.50; 1.61] <b>0.75 [0.66; 0.86]</b>	3.5% 5.9% 6.1% 3.0% 18.4%	- 25%
Type = Cheese Sahni 2014 Michaelsson (Female) 2014 Michaelsson (Male) 2014 Feart 2013 Random effects model Heterogeneity: J <sup>2</sup> = 0%, p = 0.60		0.72 [0.48; 1.08] 0.64 [0.55; 0.74] 0.75 [0.62; 0.91] 0.78 [0.44; 1.39] 0.68 [0.61; 0.77]	4.2% 6.3% 5.9% 3.1% <b>19.5</b> %	- 32%
Type = Total dairy products Feart 2013 Benetou 2011 Random effects model Heterogeneity: $I^2 = 0\%$ , $p = 0.92$	•	1.05 [0.60; 1.84] 1.02 [0.93; 1.12] 1.02 [0.93; 1.12]	3.1% 6.6% 9.7%	
Type = Cream Sahni 2014 Random effects model Heterogeneity: Not applicable	\$	1.04 [0.59; 1.85] 1.04 [0.59; 1.85]	3.1% 3.1%	400/
Random effects model Heterogeneity:/ <sup>2</sup> = 81%, p<0.01	0.5 1 2	0.87 [0.76; 1.00]	100.0%	13%



Fermented dairy products consumption is associated with attenuated cortical bone loss independently of total calcium, protein and energy intakes in healthy postmenopausal

women



#### Biver et al Osteoporos Int 2018



#### Effects of *Lactobacillus reuteri* on Bone in Older Women – The **ELBOW** Trial


Per protocol population, n=68

- A randomized, double-blind, placebo-controlled trial, ± daily supplementation with L.reuteri 6475 in older women with low BMD
- 90 women, 76 years old, randomized to placebo or L.reuteri 6475 for 12 months
- The primary and predefined outcome was relative change in volumetric BMD at the ultradistal tibia (measured with HRpQCT).



#### Results


#### Intention to treat population, n=90



#### Nilsson et al J Int Med 2018

## Effects of Fermented Milk Products on Bone

HUG 🕷 🞁



Rizzoli & Biver CTI 2018




# Veganism, vegetarianism, bone mineral density, and fracture risk: a systematic review and meta-analysis

Ev/Ctrl

Ev/Trt

Fracture

# Vegetarians & Vegans vs Omnivores



-Vegetarians and vegans, Only vegetarians,

Estimate (95%CO)


Vegetarians vs Omnivores

#### Vegans vs Omnivores

Caucasians

Asians

Iguacel et al Nutr Rev 2019



WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES



## April 2-5, 2020 Barcelona | Spain CCIB Congress Center

International Osteoporosis Foundation

WORLD'S LEADING CLINICAL CONFERENCE ON BONE, JOINT AND MUSCLE HEALTH Congress Organizer Sinklar Congress Management B.V. Congress Secretariat www.humacom.com

www.WCO-IOF-ESCEO.org